Drug-induced liver injury (DILI) is a major cause of drug attrition. Currently existing Quantitative Structure-Activity Relationship models have limited predictive capabilities for DILI. Furthermore, their practical applications were limited by lack of new hepatotoxicity data. In this study, we first collected and curated a novel set of 122 DILI-positive and 932 DILInegative drugs from online adverse drug reports using proportional reporting ratios as the signal detection method. Second, three strategies (under-sampling the majority class, synthetic minority over-sampling technique, and adjusting decision threshold approach) were employed to develop predictive classification models to cope with the unbalanced dataset. Random forest (RF) models using CDK, MACCS, and Mold2 descriptors based on the under-sampling and over-sampling strategies afforded correct classification ratio (CCR) of $0.77 and 0.78, respectively. Recursive RF models based on the last strategy tremendously reduced modeling descriptors (at most 95.4% for Mold2) while apparently improved the predictability with a consensus CCR of 0.84 (sensitivity of 0.88 and specificity of 0.79). Structural analysis showed that pyrimidine derivatives, purine derivatives, and halogenated hydrocarbon were critical for drugs' hepatotoxicity. The reporting frequency of many drugs was gender-dependent (eg, antiviral and anti-cancer drugs for males and antibacterial drugs for females) as well as age-dependent (eg, antiviral and anti-cancer drugs for the middle age group of 20-29, 30-39, and 40-49). Approximately 84% of total cases were reported during the first 6 months of administration. The curated hepatotoxicity dataset along with the predictive classification models presented here should provide insight into future studies of DILI.
Drug-induced liver injury (DILI) is a major cause of drug attrition (Kaplowitz, 2005; Stevens and Baker, 2009) . In silico modeling is a time-and cost-efficient approach to detect potential hepatotoxins early in the drug development process (Przybylak and Cronin, 2012) . Many in silico classifiers of hepatotoxicity were developed using a variety of algorithms [eg, Bayesian modeling, support vector machine, and random forest (RF)] based on chemicals' structural information (Chen et al., 2013; Ekins et al., 2010; Fourches et al., 2010; Liu et al., 2011; Mulliner et al., 2016; Rodgers et al., 2009; Zhang et al., 2016) . Other studies developed structural alerts for hepatotoxicity (Greene et al., 2010; Liu et al., 2015; Pizzo et al., 2015; Stepan et al., 2011) . In general, currently existing Quantitative Structure-Activity Relationship (QSAR) models have limited predictive capabilities for DILI (Chen et al., 2014; Przybylak and Cronin, 2012) . Furthermore, complex pathologies and toxicological pathways of hepatotoxicity (Jaeschke et al., 2002) resulted in diverse definition of the criteria for hepatotoxicity. Acquiring new hepatotoxicity data is becoming extremely difficult for researchers. As a result, the same hepatotoxic dataset might have been repeatedly investigated in many published QSAR models only differ in their structural descriptors and modeling algorithms. However, the lack of new hepatotoxicity data supporting made those models less applicable in drug discovery and less attractive to most researchers.
Post-marketing case safety reports are one of the main sources of DILI information. Given its rarity, DILI may not occur during clinical trials of a few thousand participants. However, rare liver toxic effects may emerge after approval of a drug for use by large numbers of patients (Navarro and Senior, 2006) . Spontaneous reporting systems (eg, FDA Adverse Event Reporting System) are predominately used by many organizations to collect adverse drug reactions. The Drug-Induced Liver Injury Network (DILIN) was specifically initiated to collect and analyze reporting cases of severe liver injury caused by all kinds of drugs (Hoofnagle, 2004) . Liver toxicity databases such as liverTox (Hoofnagle et al., 2013) and vigiBase (Suzuki et al., 2010) were mainly based on categorization framework of DILIN. The Liver Toxicity Knowledge Base (LTKB) (Chen et al., 2011) , which categorized FDA-approved prescription drugs into 3 categories (ie, Most-, less-, and no-DILI concern), also partially referred to patients' response to drug treatment. As mentioned before, those hepatotoxicity datasets have been extensively investigated by many researchers.
Statistical analysis such as proportional reporting ratios (PRRs) (Evans et al., 2001; Puijenbroek et al., 2002; Sakaeda et al., 2013) , reporting odds ratio (Puijenbroek et al., 2002; Sakaeda et al., 2013) , the information component (Puijenbroek et al., 2002; Sakaeda et al., 2013) , and the Empirical Bayes Geometric Mean (Sakaeda et al., 2013; Suzuki et al., 2010) have been widely used for signal detection in spontaneous reporting systems for adverse drug reactions. These methods take into account of the exposure of patients to a drug based on the frequency of reporting in the entire database. Given the relative rarity of DILI [eg, the estimated risk ranges from 1 in 10 000 to 1 in 100 000 for many drugs (Bjornsson, 2015) ], the low hepatotoxicity signals would result in the dominance of non-hepatotoxic drugs in the entire database. Approaches like under-sampling the majority class (Newby et al., 2013; Zakharov et al., 2014) , over-sampling the minority class (Chawla et al., 2002; Chen et al., 2004) , costsensitive learning (Newby et al., 2013) , and adjusting decision threshold (Zakharov et al., 2014) were widely used to cope with the imbalance of positive and negative classes. Our previous study (Zhu et al., 2016) demonstrated the adjusting decision threshold approach (eg, adjust the boundary in assigning class memberships) helped to build predictive models.
In this study, we first sought to construct a unique DILI dataset from a collection of adverse drug reports retrieved from professional websites. Thereafter, we worked on developing rigorously validated predictive in silico models to screen out chemicals with putative human hepatotoxicity, as well as identifying marked structural alerts. Patient characteristics (eg, age and gender) and drug factors (eg, drug types, treatment duration) were associated with post-marketing case safety reports.
Last, we would tentatively analyze gender and age differences in the reporting hepatotoxicity cases as well as the influence of administration duration on DILI.
MATERIALS AND METHODS
Dataset. The adverse drug reports on hepatotoxicity were retrieved from ehealthme websites (http://www.ehealthme.com/ , accessed on March 16th 2016). Complex mixtures, inorganic and organometallic compounds, herbal products, large peptides, and unspecified names or abbreviations were removed from the original datasets. A total of 3714 medications with/without hepatotoxicity reporting frequency were collected. This dataset consists of 4 parts: (1) the total reporting frequency of adverse effects for each drug and corresponding reporting frequency of hepatotoxicity; (2) patient gender; (3) patient age information which was divided into 8 groups (age 0-1, 2-9, 10-19, 20-29, 30-39, 40-49, 50-59, and >60) ; and (4) administration duration which was divided into 7 groups (duration <1 month, 1-6 months, 6-12 months, 1-2 years, 2-5 years, 5-10 years, >10 years).
Some of the drugs are identified by more than one name (ie, generic or brand names). The original SMILES of these drugs were retrieved from PubChem CACTUS web server (https://cac tus.nci.nih.gov/, last accessed March 16, 2016) . Canonical SMILES of all active pharmaceutical ingredients of these drugs were curated using ChemAxon Standardizer (v.6.2.1, ChemAxon, Budapest, Hungary) through a process of neutralization, tautomerization, aromatization, and 2D structure cleaning. All drugs were unified according to their canonical SMILES. Note that some combination drugs include 2 active pharmaceutical ingredients. In these cases, we first checked if their active pharmaceutical ingredients were DILI positive or not. Without knowing the fixed ratio of each ingredient, we randomly assigned the hepatotoxicity information of a combination drug to one of the active pharmaceutical ingredients if both of them are DILI positive. The hepatotoxicity information of combination drugs was assigned to the positive pharmaceutical ingredient if only one of their ingredients is DILI positive. For instance, Combivir is an antiviral medication containing a combination of Lamivudine and Zidovudine. Since both Lamivudine and Zidovudine are DILI positive in our dataset, we randomly assigned the hepatotoxicity information of Combivir to Zidovudine. Consequently, a set of 1587 unique drugs (632 with at least one hepatotoxicity report and 955 without hepatotoxicity report) with a total cooccurrences of 19 054 were collected for further analysis. A cooccurrence, here defined as a pair of a drug and reported hepatotoxicity, was the basis for the signal detection.
Signal detection analysis. The PRR algorithm (Evans et al., 2001) was used for signal generation from the set of 632 drugs with at least one hepatotoxicity report. As shown in the 2-by-2 contingency table (Table 1) , PRR was calculated as a/(a þ c) divided by b/(b þ d) (Evans et al., 2001) . A chi-squared for the 2-by-2 contingency table was also calculated. A set of 122 signal drugs (caused a total of 5619 drug-hepatotoxicity co-occurrences) were detected to cause more frequent DILI than expected. Patients' gender, age, and administration duration were available for 116, 118, and 85 drugs, respectively. Of the 5619 cooccurrences, gender information was available for 5293 (94.2%), 2677 (50.6%) for females and 2616 (49.4%) for males. Age information was available for 5569 cases (99.1%) and administration duration information was available for 5224 cases (93.0%).
The set of 122 signal drugs were considered as hepatotoxic according the signal detection algorithm. A set of 957 drugs without hepatotoxicity report were considered as non-hepatotoxic. The rest of the 508 drugs with weak hepatotoxicity signals were considered as marginal. Consistent analysis of this curated hepatotoxicity dataset with vigiBase (Suzuki et al., 2010) showed 85 out of 122 hepatotoxic drugs were newly identified. Among the 957 non-hepatotoxic drugs, 25 of them were listed in vigiBase. These 25 drugs were removed from non-hepatotoxic dataset in subsequent analysis (ie, only 932 non-hepatotoxic drugs left).
Quantitative structure activity relationship modeling. The set of 122 hepatotoxic and 932 non-hepatotoxic drugs were labeled as 1 (positive) and 0 (negative), respectively (Supplementary Table 1 ). The MDL MACCS public keys, calculated by using the Fingerprint node in KNIME (KNIME V3.1, 2016), were used as fingerprint descriptors to characterize chemical structures. Twodimensional chemical descriptors were calculated separately using Chemistry Development Kit (CDK, v.1.4.13, GNU Lesser General Public License) and Mold2 (v.2.0, National Center for Toxicological Research, US FDA) software. Before modeling, descriptors with low variance (standard deviation <0.001) were removed from corresponding descriptor sets. If the coefficient of determination (R 2 ) of pairwise descriptors is larger than 0.95, one of the pair was randomly removed. Consequently, QSAR models were built separately using 147 CDK, 141 MACCS, or 437 Mold2 descriptors. RF was run through the package "randomForest" (Liaw and Wiener, 2002) on the R language (v3.2.3) environment. Each RF model consists of default 500 trees and its prediction was shown as class probabilities (range from 0 to 1), which was the fraction of positive predictions in the 500 trees. To cope with the imbalanced dataset ($7.64: 1 dominance of non-hepatotoxic drugs), 3 strategies were employed: (1) under-sampling the majority class (Zakharov et al., 2014) ; (2) over-sampling the minority class using synthetic minority over-sampling technique (SMOTE) (Chawla et al., 2002) ; and (3) adjusting decision threshold approach, the proportion of DILI-positive drugs (122/ 1054 ¼ 0.1157) was used for the classification instead of the default 0.50 (ie, drugs were predicted as negative if their class probabilities were less than 0.1157, and positive otherwise). Consensus prediction (Gramatica et al., 2007; Kuz'min et al., 2009; Tropsha, 2010) was performed on the models based on CDK, MACCS, and Mold2 descriptors to seek an improvement in the prediction performance.
For the first 2 approaches, we first randomly sampled fourfifths of the whole DILI dataset as the training set ($98 hepatotoxic and $745 non-hepatotoxic compounds) and left the remaining ones ($24 hepatotoxic and $187 non-hepatotoxic compounds) as external validation. For the approach of undersampling the majority class, we then randomly sampled $98 non-hepatotoxic compounds from the negative ones ($745) to pair up with the set of $98 hepatotoxic compounds in the training set. For the approach of synthetic minority over-sampling, these 98 hepatotoxic compounds were over-sampled using SMOTE (Chawla et al., 2002) to a size of $745 to pair up with the non-hepatotoxic ones ($745) in the training set. RF models were then developed based on those under-sampled or over-sampled datasets to predict the remaining external validation sets. In general, models based on the under-and over-sampling approaches shared the same training sets and external validation sets. Both the under-and over-sampling approaches were repeated for 1000 times to ensure the reliability of those developed models. Recursive RF (Zhu et al., 2015) was performed for the approach of adjusting decision threshold to select the optimal variable set to achieve the best prediction performance. At each round, variable importance was measured by mean decrease in the predictive accuracy. The least important 20% of descriptors were recursively excluded until there were seven left. The 5-fold external cross validation (Tropsha, 2010) was performed at each round of recursive RF modeling to avoid overfitting. RF employs bagging as internal test set to estimate the generalization error of the training set (Breiman, 2001 ). Thus, we split the whole dataset into training set and external validation set for all those above approaches.
Model performance. Productivity measures such as specificity, sensitivity, and correct classification rate (CCR) were used to evaluate the performance of RF models. Specificity and sensitivity denote the true negative rate and the true positive rate, respectively. Given the imbalance of the DILI dataset, CCR, the average of specificity and sensitivity, was used to measure the overall prediction performance instead of accuracy. Coverage is the percentage of drugs in the external set within the applicability domain (AD) of the model. The AD is a similarity threshold within which drugs can be reliably predicted (Tropsha et al., 2003) .The receiver operating characteristic (ROC) curve with paired true positive (sensitivity) and false positive (1-specificity) rates (Lasko et al., 2005) was plotted for all possible thresholds for in silico models. The area under the ROC curve (AUC) was also used to quantitatively summarize the classification accuracy of a model. The R package 'AUC' (Ballings and Van den Poel, 2013) was used for the calculation.
Sub-structural analysis. Using the graph mining algorithm (Borgelt, 2007) implemented in the MoSS node in KNIME (KNIME V3.1, 2016), we searched for sub-structural fragments that show tremendously different frequency between hepatotoxic and non-hepatotoxic drugs. We configured the following parameters in the MoSS node: minimum focus support, the minimum fraction of the fragment-contained chemicals in the hepatotoxic class, was set as 6%; maximum complement support, the maximum fraction of the fragment-contained drugs in the nonhepatotoxic class, was set as 3%. The minimum fragment size (the number of non-hydrogen atoms) was set as 4 and the maximum fragment size 20.
RESULTS

Curated Dataset
A set of 1054 unique drugs with DILI information were collected and curated in Supplementary Table 1. A set of 122 hepatotoxic drugs were detected using three criteria: A minimum reporting frequency of 3, a PRR at least 2, and a Chi-squared of at least 4 (Evans et al., 2001) . Among the 122 hepatotoxic drugs, the total reporting frequency of side effects ranges from 32 for Calderol to 116 253 for Paracetamol (Acetaminophen). The reporting frequency of hepatotoxicity ranges from 3 (ie, the minimum criteria for a signal) to 544 for Paracetamol. Besides the gender, age, and administration duration, Supplementary Table 1 also showed the calculated PRR with 95% confidence intervals and Chi-squared values.
Under-Sampling the Majority Class RF models were developed based on CDK, MACCS, and Mold2 descriptors using the approach of under-sampling the majority 
Total report frequency without hepatotoxicity
a: the number of hepatotoxicity caused by drug of interest, a þ c: the total number of co-occurrences with a drug of interest, a þ b: the total number of hepatotoxicity caused by all drugs, a þ b þ c þ d: the total number of adverse effect reports in the database (19 054).
class (n ¼ 1000). A cutoff of 0.50 was used for the classification of class probabilities. The prediction performance of those 1000 RF classifiers were summarized in Table 2 . RF models based on those 3 types of descriptors showed similar performance (CCR of $0.77). The maximum CCR reached 0.89 for models based on CDK and Mold2 descriptors while the minimum one is 0.63 for CDK and MACCS. Density analysis (Supplementary Figure 1A) showed the 1000 CCR values based on CDK, MACCS, and Mold2 descriptors are normally distributed.
Synthetic Minority Over-Sampling RF models for CDK, MACCS, and Mold2 descriptors were developed using the SMOTE (n ¼ 1000), which balanced the number of hepatotoxic and non-hepatotoxic classes. A cutoff of 0.50 was first used for the classification of class probabilities. However, all the models shared low sensitivity (eg, 0.38, 0.38, and 0.41 for CDK, MACCS, and Mold2, respectively) and high specificity (eg, $0.98 for CDK, MACCS, and Mold2). The AUC of those models based on CDK, MACCS, and Mold2 was $0.87 (Table 3) , which is quite high for binary classification models (AUC of random predictor is 0.50). This phenomenon indicated the cutoff of 0.50 was not appropriate. As such, we incorporated the adjusting decision threshold approach into the analysis to classify the class probabilities and the results are listed in Table 3 . The prediction performance of models based on SMOTE was slightly better than those using the under-sampling approach in terms of CCR. Density analysis (Supplementary Figure 1B) showed the 1000 CCR values based on CDK, MACCS, and Mold2 descriptors are also normally distributed.
Adjusting Decision Threshold Modeling
Recursive RF modeling based on the whole DILI dataset (1054 drugs) requires assessing the model performance at each round. The adjusting decision threshold approach (ie, decision threshold of 0.1157) was applied at each round to calculate the specificity, sensitivity, and CCR. The performance of recursive RF modeling based on 3 types of descriptors (CDK, MACCS, and Mold2) was shown in Table 4 . CDK, MACCS, and Mold2 descriptors were reduced from 147, 141, and 437 to 8, 26, and 20, respectively, through the recursive RF modeling. The overall performance of those models with reduced descriptors was better than those based on multiple under-and over-sampling approaches. A consensus prediction based on the three QSAR models, which affords a CCR of 0.84 with a sensitivity of 0.88 and a specificity of 0.79, is tremendously better than individual ones (Table 4 ). Figure 1 showed the ROC curves of classification performance for the 3 individual and consensus models. The AUC of the consensus model (0.93) is also much higher than the individual models' AUCs (ie, 0.88, 0.87, and 0.89 for CDK, MACCS, and Mold2, respectively).
The important descriptors selected by recursive RF modeling and their corresponding mean decrease in accuracy are shown in Supplementary A relative large AD (Z ¼ 3) was used in the evaluation of model performance. The effect of AD on the model coverage and performance was show in Supplementary Table 3 . A stringent AD indeed can enhance the CCR of RF models based on CDK and MACCS descriptors. However, the prediction performance of Mold2 model showed no dependency on the AD.
Structural Alerts
Descriptor analysis provides limited information on chemical features related to liver toxicity. To explore more potential structural alerts for hepatotoxicity, we searched the 122 hepatotoxic and 932 non-hepatotoxic drugs for conspicuous structural differences using the MoSS node in KNIME (KNIME V3.1, 2016). Five substructures (pyrimidin-4-amine, methylpyrimidine, purine, aminopyrimidine, trifluoroethane) were found responsible for drug's hepatotoxicity (Table 5 ). Frequency analysis shows that these 5 sub-structures appear in hepatotoxic drugs more frequently than in non-hepatotoxic ones. In general, these 5 sub-structures can be classified into 3 categories: pyrimidine derivatives (pyrimidin-4-amine, methylpyrimidine, and aminopyrimidine), purine derivatives, and halogenated hydrocarbon (trifluoroethane). Chemicals containing those sub-structures should be cautiously investigated and experimentally verified in the preclinical phase.
Reported Drugs by Patients' Gender and Age
A total of 5293 co-occurrences were caused by a set of 116 drugs with patients' gender information. Seventeen drugs only caused hepatotoxicity in female with a total of 140 co-occurrences. Six out of these 17 drugs only have minimum criteria of 3 reports. Among these 17 drugs, Ketoconazole (Extina, Nizoral, Xolegel) caused 36 liver injury reports, followed by Delsym (Dextromorphan, Hydrobromide) with 25 reports. Eight out of 116 drugs with available patients' gender information caused hepatotoxicity only in males with a total of 122 reports. Two out of these 8 drugs only have minimum criteria of 3 reports. Among these 8 drugs, Didanosine (Videx Ec) caused the largest number of 48 liver injury reports, followed by Hydroxyurea (Droxia, Hydrea) with 27 reports.
Paracetamol (acetaminophen), a medication used to treat pain and fever, was the most commonly reported drug with the remarkably highest number of reports from both females (321) and males (223) ( Table 6 ). As the second frequently reported drug in male, Combivir (Retrovir, Zidovudine, Trizivir), an antiviral medication, was listed as the 4th frequently reported drug in female. Accordingly, the second most reported drug in females (Nevirapine/Viramune) was listed as the 5th in males (Table 6 ). In general, males reported more antiviral cases than females. Females reported more antibacterial cases (138 reports for Bactrim) than males (0 reports in top 10 drugs). Liver injury induced by anti-cancer drugs was also predominately reported by males. There were three anti-cancer drugs (a total of 348 reports for Cytoxan, Fludara, and Cytarabine) in the top 10 most commonly reported hepatotoxic drugs for males, while only one (94 reports for Cytoxan) for females (Table 6) . A total of 5569 reports were caused by a set of 118 drugs with patients' age information, the number of reports is 127, 281, 500, 709, 833, 1154, 891, 1074 for age groups of 0-1, 2-9, 10-19, 20-29, 30-39, 40-49, 50-59 , and >60, respectively. Patients older than 30 years accounted for 71.0% of those reported hepatotoxicity cases. Figure 2 gives the age distribution of the top 10 most reported drugs. Paracetamol showed nearly even distribution among all the 8 age groups with reported cases of 52, 68, 53, 53, 41, 87, 82, and 108. Reported cases for 2 antiviral medications Combivir and Nevirapine concentrated on the middle age groups (ie, age 20-29, 30-39, and 40-49) (Figure 2 ). Other reports on antiviral drugs (eg, Epivir, Stavudine, and Truvada) also showed similar age distribution.
Administration Duration Analysis
A total of 5224 cases were caused by 85 drugs with available administration duration information. The reported cases were 2813, 1575, 229, 199, 251, 125 , and 32 for 7 administration duration groups of <1 month, 1-6 months, 6-12 months, 1-2 years, 2-5 years, 5-10 years, and >10 years, respectively. Approximately 84% of total cases were reported in the first 6 months of administration. Only 11.6% of total cases occurred after 1 year administration. Most of liver injury caused by the top 10 drugs was also reported during the first 6 months. For instance, $70.2% patients reported liver injury caused by Paracetamol in the first month and 18.6% of them reported liver injury during the interval of 1-6 months ( Figure 3) . Similarly, $87.2% and 97.5% patients reported liver injury caused by Nevirapine and Cytoxan during the first 6 months. Cyclosporine, an immunosuppressant drug used in organ transplantation, caused 50% total cases of liver injury after administration duration of 6 months. Stavudine, a drug prescribed to treat HIV infection, accounted for 35.1% total cases of liver injury after 2-year administration duration.
DISCUSSION
Novelty of This DILI Dataset
The 85 hepatotoxic drugs showed no overlap with vigiBase (Supplementary Table 4 ) triggered a total of 2839 reports with an average of 33.4 reports per drug (Table 7) . Nevertheless, the remaining 37 drugs that were consistent to vigiBase accounted for a total of 2780 reports with an average of 75.1 reports per drug. The overlap of DILI positive chemicals in our dataset with FDA Human Liver Adverse Effects Database (HLAED) (Matthews et al., 2004) and LTKB datasets (Chen et al., 2011) were 31 and 29, respectively (Table 7 ). In total, the overlap of our dataset with the other 3 datasets was 64 which meant that 58 drugs were newly identified DILI positive chemicals. Of the overlap of 31 chemicals with HLAED, 8 DILI negative drugs and 9 drugs without DILI information were identified as DILI positive in our dataset (Supplementary Table 4) . Of the overlap of 29 chemicals with LTKB, 6 non-DILI-concern drugs and 5 Less-DILI-concern drugs were identified as DILI positive in our dataset (Supplementary Table 4 ). Nevertheless, these newly identified DILI positive drugs averagely caused much less liver injury reports ($1/3-1/2) than those already existed in vigiBase, HLAED, and LTKB (Table 7) . It is reasonable that newly identified DILI positive drugs received less reports. As adverse side effects are continually being reported, one could expect drugs in the marginal category to be identified as hepatotoxic. It is worth noting that our curated DILI positive data should be very cautiously used until they are rigorously analyzed and validated 
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Leflunomide/pyrimidine synthesis inhibitor through standardized definitions and instruments such as the DILIN (Hoofnagle, 2004) .
Model Performance
The occurrence of DILI is rare with respect to the large amount of commercially available drugs. We chose the under-sampling the majority class (Newby et al., 2013; Zakharov et al., 2014) , SMOTE (Chawla et al., 2002) , and adjusting decision threshold (Zakharov et al., 2014; Zhu et al., 2016) to cope with the imbalanced hepatotoxicity data. However, the under-sampling strategy suffers from the loss of information from the original training set. Our strategy of using under-sampling of the nonhepatotoxic chemicals achieved average CCR of 0.77 (Table 2) . The SMOTE boosted up the minority class to pair up with the majority class and avoided the disadvantage of information loss caused by under-sampling. But it also cannot augment the information of the minority class in our dataset. Thus, the cutoff for its class probabilities still cannot be lifted from 0.1157 (ie, 122/1054) to 0.50 as was used for a normal balanced dataset. The comparison of SMOTE with under-sampling approach or decision threshold adjusting needs further comprehensive study. For this study alone, the approach of adjusting decision threshold showed the best predictive performance (eg, average CCR of 0.80 and consensus CCR of 0.84) ( Table 4) . Together with our previous study (Zhu et al., 2016) , we confirmed that the adjusting decision threshold approach is an appropriate choice for imbalanced dataset. Previously, Greene et al. (2010) developed a knowledge-based expert system (Derek for Windows) for hepatotoxicity using structural alert which afforded prediction accuracy of 0.56. Ekins et al. (2010) built Bayesian classifiers for hepatotoxic chemicals with prediction accuracy of 0.60. In the most recent study, Mulliner et al. (2016) developed 18 models for human and preclinical hepatotoxicity endpoints. The prediction accuracy of those models for internal validation sets ranges from 0.73 to 0.83 and for external validation sets 0.38 to 0.64. Many other rigorously external validated classification models based on purely chemical descriptors also suffered from unsatisfactory predictive performance (Chen et al., 2014; Przybylak and Cronin, 2012) . Comparing with these previous studies, the predictive performance of our models (Table 4) was quite acceptable.
Sub-Structural Alerts
The important CDK, MACCS, and Mold2 descriptors listed in Supplementary Table 2 contributed much on model performance. However, these descriptors were too implicit to provide useful chemical structural information related to liver toxicity. The widespread use of structural alerts provides a straightforward way to detect potential toxic drugs and reduce the risk of drug discovery and development failures. The structural alerts derived in this study all showed significant high frequency in hepatotoxic drugs than that in non-hepatotoxic ones (Table 5) . Purine and pyrimidine analogs interfere with DNA synthesis. Most pyrimidine analogs were antibacterial, antiviral, or antibiotic chemicals with more than one ring (Table 5) . Through comparative analysis with recent studies on hepatotoxic structural alerts (Liu et al., 2015; Pizzo et al., 2015) , we found no report of similar sub-structures. Thus, the pyrimidine and purine analogs as structural alerts for hepatotoxicity need further validation. Trifluoroethane was listed as a structural alert for hepatotoxicity, which was consistent with one previous study listed the halogen atom bonded to a sp 3 carbon as a structural alert for hepatotoxicity (Liu et al., 2015) . Oxidative defluorination (Olson et al., 1990) would generate reactive oxygen species (ROS) during P450 catalysis. ROS was known to mediate liver injury (Jaeschke, 2011; Llacuna et al., 2009) .
Reported Drugs and Patient Information
Paracetamol (acetaminophen) has long been reported to induce liver injury (Simon, 1985) . A recent study showed women reported the majority of acute liver injury (65%) and acute liver failure (77%) induced by paracetamol (Rubin et al., 2016) . In our study, 59% of the liver injury induced by paracetamol were reported in females (Table 6 ). The gender difference may suggest physiologic differences in paracetamol metabolism and sensitivity to hepatotoxicity by sex (Rubin et al., 2016) . Other liver injury reports were seemly caused in targeted patient population. Cytoxan (cyclophosphamide), Fludara (Fludarabine), and Cytarabine were anti-cancer drugs often used by men for the prostatic cancer treatment (Barnetson et al., 2008; Dhani et al., 2012; Nelius et al., 2011) . Correspondingly, those 3 drugs had a higher number of hepatotoxicity reports for males (142 for Cytoxan, 111 for Fludara, and 95 for Cytarabine) than for females (94 for Cytoxan, 23 for Fludara, and 55 for Cytarabine). Hepatotoxicity reports for antiviral drugs were also strongly associated with males which was consistent with previous research (Petronijevic and Ilic, 2013) . The regional HIV prevalence and geographical differences might explain male predominance in reporting as men comprised more than 70% of the people living with HIV in North America and Western and Central Europe (Petronijevic and Ilic, 2013) . Consistent with previous studies (Petronijevic and Ilic, 2013; Petronijevic et al., 2011) , hepatotoxicity reports for antibacterial drugs (Bactrim and Isoniazid in Table 6 ) were strongly associated with females in our study. Furthermore, Prelay (Rezulin), an anti-hyperglycemic drug which had been withdrawn in 2000, was also strongly associated with female gender (100 reports from females and only 32 reports from males). Thus, patient gender needs to be specifically investigated for hepatotoxic effects of antibiotics and anti-hyperglycemic drugs.
The nearly even distribution of reports on the hepatotoxicity of paracetamol among different age groups (Figure 2 and Supplementary Table 1) indicated its wide administration among different ages. Almost all reports of antiviral medications (eg, Combivir, Nevirapine, Epivir, Stavudine, and Truvada in Figure 2 ) concentrated on the middle age groups (20-29, 30-39, and 40-49) . Most anti-cancer drugs (Cytoxan and Cytarabine) were reported among the middle and older age groups (>20-29). Only Cosmegen (Dactinomycin) was reported among groups of age 0-1, 2-9, and 10-19 since it was a highly toxic medication for the treatment of childhood rhabdomyosarcoma (Carli et al., 1988) . Thus, target patient population was subjected to the adverse effect of drugs.
In this study, we curated a new DILI dataset from online adverse drug reports. We also put extensive effort into model development and structural alert analysis. Recursive RF modeling in combination with the adjusting decision threshold approach was determined to be the approach to cope with imbalanced dataset to improve models' predictive performance as well as reduce unimportant descriptors. Patient gender and age and drugs' administration duration were all determined to be associated with the hepatotoxicity of specific drug types. The curated hepatotoxicity dataset presented and predictive models presented here will facilitate further studies on DILI as additional patient data are incorporated.
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